ContraFect Corporation Stock Predictions
Currently predicting for Mon, 30 Jan 2023Trading levels for CFRX
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 0.0794 | 15.96 % | |
| R2 | 0.0753 | 9.88 % | ||
| R1 | 0.0727 | 6.13 % | ||
| Current price: | 0.0685 | |||
| Support | S1 | 0.0644 | -6.03 % | |
| S2 | 0.0618 | -9.79 % | ||
| S3 | 0.0576 | -15.86 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 0 | . | |
| R2 | 0 | . | ||
| R1 | 0 | . | ||
| Current price | 0.0685 | |||
| Support | S1 | 0 | . | |
| S2 | 0 | . | ||
| S3 | 0 | . |
CFRX Predictions History
1 year ago
issanikko.219348 predicted that
CFRX
for 2021-03-29 is going
2 years ago
mike waller predicted that
CFRX
for 2020-12-07 is going
2 years ago
Joseph Angelillo predicted that
CFRX
for 2020-02-20 is going
About ContraFect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the in... CFRX Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
